US 70

0823

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/928,047

Source: OIPE

Date Processed by STIC: 8/23/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.
Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:
http://www.uspto.gov/web/offices/pac/checker

OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/928,047

DATE: 08/23/2001
TIME: 16:01:06

Input Set : A:\ES.txt
Output Set: N:\CRF3\08162001\I928047.raw

Does Not Comply
Corrected Diskette Needed

4 <110> APPLICANT: Cantor, Thomas L.
6 <120> TITLE OF INVENTION: Cyclase Inhibiting Parathyroid Hormone Antagonists or Modulators and
7 Osteoporosis
C--> 9 <140> CURRENT APPLICATION NUMBER: US/09/928,047
C--> 9 <141> CURRENT FILING DATE: 2001-08-10
W--> 0 <130> FILE REFERENCE:
9 <160> NUMBER OF SEQ ID NOS: 5
11 <170> SOFTWARE: Microsoft Word 2000 - ASCII format

pp 1-2

ERRORED SEQUENCES

14 <210> SEQ ID NO: 1
16 <211> LENGTH: 83 [integer length]
18 <212> TYPE: PRT
20 <213> ORGANISM: human parathyroid hormone peptide fragment
22 <400> SEQUENCE: 1
24 Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
25 1 5 10 15
27 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
28 20 25 30
30 His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala
31 35 40 45
33 Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu
34 50 55 60
36 Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn
37 65 70 75
E--> 39 Val Leu Thyr Lys Ala Lys Ser Gln
40 80
44 <210> SEQ ID NO: 2
46 <211> LENGTH: 51 [integer length]
48 <212> TYPE: PRT
50 <213> ORGANISM: human parathyroid hormone peptide fragment
52 <400> SEQUENCE: 2
54 Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
55 1 5 10 15
57 Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His
58 20 25 30
60 Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn Val Leu
61 35 40 45
E--> 63 Thyr Lys Ala Lys Ser Gln
64 50
68 <210> SEQ ID NO: 3
70 <211> LENGTH: 82 [integer length]
72 <212> TYPE: PRT
74 <213> ORGANISM: human parathyroid hormone peptide fragment
76 <400> SEQUENCE: 3

delete

invalid

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/928,047

DATE: 08/23/2001
TIME: 16:01:06

Input Set : A:\ES.txt
Output Set: N:\CRF3\08162001\I928047.raw

```
     78 Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser
     79 1               5                  10                  15
     81 Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
     82             20                  25                  30
     84 Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly
     85             35                  40                  45
     87 Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser
     88             50                  55                  60
     90 His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn Val
     91             65                  70                  75
E--> 93 Leu Thyr Lys Ala Lys Ser Gln
     94             80
     98 <210> SEQ ID NO: 4
    100 <211> LENGTH: 57 [integer length]
    102 <212> TYPE: PRT
    104 <213> ORGANISM: human parathyroid hormone peptide fragment
    106 <400> SEQUENCE: 4
    109 Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala
    110 1               5                  10                  15
    112 Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn
    113             20                  25                  30
    115 Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys
    116             35                  40                  45
E--> 118 Ala Asp Val Asn Val Leu Thyr Lys Ala Lys Ser Gln
    119             50                  55
    123 <210> SEQ ID NO: 5
    125 <211> LENGTH: 57 [integer length]
    127 <212> TYPE: PRT
    129 <213> ORGANISM: human parathyroid hormone peptide fragment
    131 <400> SEQUENCE: 5
    133 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu
    134 1               5                  10                  15
    136 Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
    137             20                  25                  30
    139 Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp
    140             35                  40                  45
    142 Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val
    143             50                  55                  60
    145 Glu Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val
    146             65                  70                  75
E--> 148 Asn Val Leu Thyr Lys Ala Lys Ser Gln
E--> 149             80
```

VERIFICATION SUMMARY DATE: 08/23/2001
PATENT APPLICATION: US/09/928,047 TIME: 16:01:07

Input Set : A:\ES.txt
Output Set: N:\CRF3\08162001\I928047.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No
L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:0 M:201 W: Mandatory field data missing, FILE REFERENCE
L:39 M:333 E: Wrong sequence grouping, Amino acids not in groups!
L:39 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:63 M:333 E: Wrong sequence grouping, Amino acids not in groups!
L:63 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:93 M:333 E: Wrong sequence grouping, Amino acids not in groups!
L:93 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:118 M:333 E: Wrong sequence grouping, Amino acids not in groups!
L:118 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:148 M:333 E: Wrong sequence grouping, Amino acids not in groups!
L:148 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:149 M:252 E: No. of Seq. differs, <211>LENGTH:Input:57 Found:84 SEQ:5

UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 0 9 2002

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/928,047	08/10/2001	Thomas L. Cantor	

CONFIRMATION NO. 7857

FORMALITIES LETTER

OC000000006946155

Brian D. Voyce
Suite C204
1100 Possum Trot Road
North Myrtle Beach, SC 29582

Date Mailed: 10/22/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial Number: 09/928,047

Filing Date: August 10, 2001

Applicant: Thomas L. Cantor

Title: Cyclase Inhibiting Parathyroid Hormone Antagonists or Modulators and Osteoporosis

Statement for a Sequence Listing

Assistant Commissioner for Patents
Washington, DC 20231

Statement for a Sequence Listing

In accordance with 37 CFR 1.821(f) and (g), the diskette submitted has computer readable information with the same content as is found on the submitted written sequence listing and as supported by the filed specification.

If the examiner has any further questions, Applicant requests that the Examiner call their attorney at 843-272-1471.

Respectfully Submitted:

Date: October 25, 2001

Brian D. Voyce
Attorney for Applicant

SEQUENCE LISTING

<110> Cantor, Thomas L.

<120> Cyclase Inhibiting Parathyroid Hormone Antagonists or Modulators and Osteoporosis

<140> Us/09/928,047

<141> 2001-08-10

<160> 5

<170> Microsoft Word 2000 - ASCII format

<210> 1

<211> 83

<212> PRT

<213> human parathyroid hormone peptide fragment

<400> 1

Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
20 25 30

His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala
35 40 45

Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu
50 55 60

Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn
65 70 75

Val Leu Thr Lys Ala Lys Ser Gln
80

<210> 2

<211> 51

<212> PRT

<213> human parathyroid hormone peptide fragment

<400> 2

Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
1 5 10 15

Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His
20 25 30

Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn Val Leu
35 40 45

Thr Lys Ala Lys Ser Gln
50

<210> 3

<211> 82

<212> PRT

<213> human parathyroid hormone peptide fragment

<400> 3

Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser
1 5 10 15

Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly
35 40 45

Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser
50 55 60

His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val Asn Val
65 70 75

Leu Thr Lys Ala Lys Ser Gln
80

<210> 4

<211> 57

<212> PRT

<213> human parathyroid hormone peptide fragment

<400> 4

Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala
1 5 10 15

Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn
20 25 30

Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys
35 40 45

Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
50 55

<210> 5

<211> 57

<212> PRT

<213> human parathyroid hormone peptide fragment

<400> 5

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu
1 5 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30

Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp
35 40 45

Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val
50 55 60

Glu Ser His Glu Lys Ser Leu Gly Glu Ala Asn Lys Ala Asp Val
65 70 75

Asn Val Leu Thr Lys Ala Lys Ser Gln
80